Floatz logo

Irinotecan

Endocrine System Diseases

Xiaoxiang ChenSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Endocrine System Diseases cohort.

Asset / SponsorPhaseRating
Hcg
Merck KGaA, Darmstadt, Germany
Phase 3BB
TESTOSTERONE UNDECYLATE
Craig Hospital
Phase 4BB
Msj-0011
Merck KGaA, Darmstadt, Germany
Phase 3BB
Follitropin Alpha
Merck KGaA, Darmstadt, Germany
Phase 3BB
Metformin
Assiut University
Phase 2B

View all 27 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →